Coeptis Therapeutics, Inc. (COEP)
US — Healthcare Sector
Automate Your Wheel Strategy on COEP
With Tiblio's Option Bot, you can configure your own wheel strategy including COEP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COEP
- Rev/Share 0.6268
- Book/Share 4.2677
- PB 4.3402
- Debt/Equity 0.2839
- CurrentRatio 0.8229
- ROIC -1.0141
- MktCap 32151636.0
- FreeCF/Share -2.3146
- PFCF -4.5201
- PE -2.8489
- Debt/Assets 0.1367
- DivYield 0
- ROE -1.8281
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders
COEP,
PPBI
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Read More
About Coeptis Therapeutics, Inc. (COEP)
- IPO Date 2020-12-17
- Website https://coeptispharma.com
- Industry Biotechnology
- CEO Mr. David Mehalick
- Employees 5
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.